Jade Therapeutics to use BioTime technology for sustained-release ophthalmic drugs
This article was originally published in Scrip
Alameda, California-based stem cell technology developer BioTime entered into an exclusive sublicense and supply agreement for its HyStem hydrogels and certain other patented technologies with Jade Therapeutics of Salt Lake City, Utah, which is developing a sustained-release drug delivery platform for ophthalmic indications.
You may also be interested in...
Aspen Neuroscience, Pandion and iTeos raised $70m, $80m and $125m, respectively. Also, Glide Healthcare closed a €416m ($450m) fund; ElevateBio, Kallyope and SutroVax reveal VC mega-rounds; and Dragonfly adds new funding to its partnering proceeds.
Approved in February as an on-demand remedy, Nurtec will be filed for migraine prevention after success in Phase III. It could be the first oral preventive therapy and first dual purpose migraine drug.
Clinical trials in a range of diseases continue to be impacted by concerns about patient safety and health care resources as the COVID-19 pandemic grows.